The FDA has slapped a clinical hold on a combo therapy using Advaxis’$ADXS axalimogene filolisbac along with AstraZeneca’s approved PD-L1 Imfinzi following the death of a patient in their Phase I/II trial.
Immutep Limited (ASX:IMM) (IMMP) (“Immutep” or the “Company”) has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), through a subsidiary, to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in a new clinical trial that will evaluate the combination in several different solid tumours.
Come this spring adults won’t be the only ones with their own line of Fitbit trackers. The company recently announced a new set of products including the Fitbit Ace, which is a tracker designed for children 8 years old and up, as well a much anticipated new smartwatch, the Fitbit Versa.
Science 37, a trailblazing company focused on “site-less” clinical trials, announced today a strategic alliance with Novartis that will support the development of its new decentralized clinical trial (DCT) offerings. This three-year commitment will enable a more extensive portfolio of trials powered by the Network Oriented Research Assistant (NORA®), Science 37’s proprietary technology platform that enables patients to participate in clinical research regardless of their geographical location using mobile devices and telemedicine services.
Stuart McGuigan took on his role as CIO of industry behemoth Johnson & Johnson in 2012. That was around the same time that Alex Gorsky joined the company as CEO. Since then, part of Gorsky’s mission has been to help J&J focus on technology, McGuigan said in an interview at HIMSS this week.
Panther Orthopedics has won FDA approval for its implantable orthopedic fixation device. The 510(k) nod clears Panther to sell a device designed to deliver continuous compression during bone healing while allowing joint motion.
AMRA has signed a new agreement to integrate its body composition analysis into Siemens Healthineers Digital Ecosystem for increased access to healthcare professionals and researchers. Intended to aid in disease prediction, AMRA’s body composition analysis is an automated method designed to convert a six-minute whole body MRI scan into 3D-volumetric fat and muscle measurements.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.